PhRMA Statement on Medicare, Medicaid Oncology Care Model
Washington, D.C. (February 12, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) executive vice president, Lori Reilly, issued the following statement on the Center for Medicare & Medicaid Innovation’s (CMMI) announcement of its Oncology Care Model demonstration program, which will test a new approach for paying doctors for their care of cancer patients:
“CMMI’s Oncology Care Model holds significant implications for patient care and continued progress against cancer. We appreciate the considerable work CMMI has put into the design of this model and the steps the agency has taken to support patient navigation and care quality. However, we are concerned that, as currently designed, the model falls short of the mark and could have the unintended effect of creating patient access barriers to beneficial tests and treatment options, including cancer medicines covered under the successful Medicare Part D drug benefit. Consistent with our prior feedback to CMMI, we believe alternative payment models like the Oncology Care Model must start with a foundation of patient engagement and care coordination, include stronger accountability for delivering clinical and care outcomes that matter to patients and provide a mechanism to support access to new tests and treatments.
“PhRMA looks forward to continue working with CMMI in support of care models that advance the efficient delivery of high-quality, patient-centered care.”
PhRMA’s Principles for Payment and Delivery System Reforms can be found here: http://www.phrma.org/phrma-principles-for-payment-and-delivery-system-reforms.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $550 billion in the search for new treatments and cures, including an estimated $51.1 billion in 2013 alone.
Connect with PhRMA
For information on how innovative medicines save lives, please visit: